Biopharmas raising money in public or private financings, including: Ampio, Anheart, Bellus, Cargene, Deliver, Erytech, Evolus, Global Blood, Neurosense, Phosplatin, Propanc, Relmada and Zealand.
Endogena Therapeutics Inc., of San Francisco, has raised another $20 million in a series A funding round to progress a regenerative medicine that could use stem cells to “heal” the damage caused by eye disease retinitis pigmentosa (RP).
Canbridge Pharmaceuticals Inc. has raised HK$604 million ($77.4 million) with a listing on the Hong Kong stock exchange, selling about 56.3 million shares (1228.HK) at HK$12.18 per share. The shares fell to HK$8.90 at the close of trading Dec. 10. Almost half the funds will support advancement of Canbridge’s lead candidate, CAN-008, a glycosylated CD95-Fc fusion protein in phase II testing for glioblastoma, while another quarter will support other major pipeline programs.
Avistone Biotechnology Co. Ltd. raised more than $200 million to support its oncology drug development and the acquisition Pearl Biotechnology Co. Ltd. with the aim of creating a “fully-integrated” targeted oncology platform. Vivo Capital LLC led the financing, with participation from Bain Capital LP. and Primavera Capital Group.
As Omicron spreads throughout Europe there’s a pressing need for new therapies that could reduce the burden on hospitals by preventing COVID-19 symptoms from escalating to a critical point. Apogenix GmbH, of Heidelberg, Germany, is pushing a potential new therapy into phase III that could be added to the armamentarium against COVID-19 with €20.7 million (US$23.4 million) government funding.
It’s been more than six years since the FDA’s first approval of an oncolytic virus – Amgen Inc.’s melanoma drug Imlygic (talimogene laherparepvec) – and it’s easy to argue that progress in the field has been overshadowed by success with other immunotherapy types such as checkpoint inhibitors. Though the FDA hasn’t approved any more oncolytic viruses since then, Phoenix-based Oncomyx Therapeutics Inc. is one of several companies trying to change that.
Newpath Partners closed its second fund with a $350 million raise, to continue its model of backing scientist-entrepreneurs during the earliest stages of company formation. The Boston-based firm works closely with a tight circle of influential scientific leaders to establish firms with high levels of scientific originality – and high ambitions to match.
LONDON – Merck KGaA has increased the size of its corporate venture fund M Ventures to €600 million (US$676.4 million), to be invested over the next five years. This is the third increase in the financial commitment to the evergreen fund following its formation as Merck Serono Ventures in 2009, with €40 million. Since then, it has backed more than 80 companies. The larger fund will allow M Ventures to further grow the number and the size of its investments but, said Hakan Goker, managing director of M Ventures, “We will not change the strategy per se.”
RSS
